-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JANX-008 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JANX-008 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JANX-008 in Metastatic Colorectal Cancer Drug Details: JANX-008 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-718 in Burkitt Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-718 in Burkitt Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-718 in Burkitt Lymphoma Drug Details: KITE-718 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naptumomab Estafenatox in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naptumomab Estafenatox in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naptumomab Estafenatox in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naptumomab Estafenatox in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naptumomab Estafenatox in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naptumomab Estafenatox in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Product Insights
NewUreter Cancer – Drugs In Development, 2024
Empower your strategies with our Ureter Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra, and enlarged lymph nodes in the groin area. Risk factors include smoking. Treatment includes surgery, chemotherapy, and radiation therapy. The Ureter Cancer drugs in development market research report provide comprehensive information on...
-
Product Insights
NewUrethral Cancer – Drugs In Development, 2024
Empower your strategies with our Urethral Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Urethral cancer is a condition in which cancerous (malignant) cells form tumors in the tissues of urethra. Urethra is the tube through which urine flows out of the bladder. A history of bladder cancer can affect the risk of urethral cancer and it occurs more often in men than in women. The symptoms include blood in urine, discharge or bleeding from the...